Study of Safety of RVL-1201 in Treatment of Blepharoptosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Blepharoptosis

In brief

Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.

Key facts

Study ID
NCT03536949
Run by
RVL Pharmaceuticals, Inc.
People needed
234
Starts
2018-06-20
Expected to finish
2019-03-27
Last updated by the study team
2020-09-16

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.